Trevi Therapeutics (TRVL) Prices 5.5M Share IPO at $10/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Trevi Therapeutics (TRVI) IPO Opens Modestly Lower
May 7, 2019 12:57 PM EDTToday's IPO for Trevi Therapeutics (NASDAQ: TRVI) opened for trading at $9.50 after pricing 5,500,000 shares at $10.
The offering was led by SVB Leerink, Stifel, BMO, and Needham & Company.
About the Company:
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically... More
